The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis

Eur Respir J. 2018 Mar 22;51(3):1701643. doi: 10.1183/13993003.01643-2017. Print 2018 Mar.

Authors

Christine M Halleux^{1

2}, Dennis Falzon^{3

2}, Corinne Merle⁴, Ernesto Jaramillo³, Fuad Mirzayev³, Piero Olliaro⁴, Karin Weyer³

Affiliations

¹ Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization (WHO), Geneva, Switzerland halleuxc@who.int.
² Both authors contributed equally.
³ Global TB Programme (GTB), World Health Organization (WHO), Geneva, Switzerland.
⁴ Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization (WHO), Geneva, Switzerland.

PMID: 29567719
DOI: 10.1183/13993003.01643-2017

No abstract available

Publication types

Editorial

MeSH terms

Antitubercular Agents / therapeutic use
Communicable Disease Control
Databases, Factual*
Diarylquinolines / therapeutic use
Humans
Infectious Disease Medicine
Isoniazid / therapeutic use
Mycobacterium tuberculosis
Nitroimidazoles / therapeutic use
Oxazoles / therapeutic use
Patient Safety
Public Health
Rifampin / therapeutic use
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / epidemiology*
World Health Organization

Substances

Antitubercular Agents
Diarylquinolines
Nitroimidazoles
OPC-67683
Oxazoles
bedaquiline
Isoniazid
Rifampin

Grants and funding

001/WHO_/World Health Organization/International